FDA Approves Treg Cell Therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

  • By

  • Kathryn Wighton

  • July 1, 2026

  • 2 min

Share

  • 1

    The FDA approved Tregzi, the first regulatory T-cell-based immunotherapy for chronic graft-versus-host disease in blood cancer patients.

  • 2

    Tregzi is composed of donor-derived regulatory T cells and conventional T cells from an 8/8 HLA-matched donor.

  • 3

    The approval was based on the PRECISION-T trial, which included 187 adult patients with blood cancers.

  • 4

    One-year chronic GVHD-free survival was 78% with Tregzi, compared to 38% with standard stem cell transplant.

  • 5

    The most common side effects of Tregzi were infections, with no severe infusion reactions reported during the study.

Original Source(s)

FDA Approves Treg Cell Therapy

  • by Kathryn Wighton

  • July 1, 2026

Related Content

Low IMA Ligation Did Not Significantly Reduce Leaks

A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

CDC Updates Cyclosporiasis Surveillance

More than 5,100 additional reports require further analysis as federal and state partners investigate several outbreaks and work to identify their sources.